Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Platelet-Rich Plasma Reduces Sternal Wound Infections

By HospiMedica International staff writers
Posted on 03 Jun 2015
A new study shows that using platelet–rich plasma (PRP) inside the sternotomy wound can significantly reduce the occurrence of infections following cardiac surgery.

Researchers at Magna Graecia University (Catanzaro, Italy) and Pugliese Ciaccio Hospital (Catanzaro, Italy) conducted a study involving 1,093 consecutive patients who underwent cardiac surgery through median sternotomy between January 2007 and January 2012 to evaluate the effectiveness of PRP applied inside the sternotomy wound in reducing the effect of sternal wound infections, both superficial and deep. More...
Antibiotic prophylaxis protocols remained unchanged throughout the study.

The study group included those who received the PRP applied inside the sternotomy wound before closure; the control group included patients who received a median sternotomy, but without the application of PRP. The results showed that the occurrence of deep sternal wound infections was significantly higher in the control group (1.5%) than in the study group (0.2%). In addition, superficial sternal wound infection rates were significantly higher in the control group than in the study group (2·8% versus 0.5%, respectively). The study was published on May 21, 2015, in International Wound Journal.

“Despite the large choice of wide-spectrum antibiotic therapy, deep sternal wound infection following cardiac surgery is a life-threatening complication worldwide,” concluded lead author Giuseppe Serraino, MD, of the cardiac surgery unit at Magna Graecia University, and colleagues. “The use of PRP can significantly reduce the occurrence of deep sternal wound infection and superficial sternal wound infections in cardiac surgery.”

PRP is blood plasma that has been enriched with platelets. The preparation process involves the collection of the patient's whole blood, which undergoes centrifugation to separate the PRP aliquot from platelet-poor plasma and red blood cells; the process concentrates the platelets roughly five-fold. As a concentrated source of autologous platelets, PRP contains several different growth factors and other cytokines that stimulate healing of bone and soft tissue. PRP has been investigated and used as a clinical tool for several types of medical treatments, including nerve injury, tendinitis, osteoarthritis, bone repair and regeneration, and plastic and oral surgery.

Related Links:

Magna Graecia University
Pugliese Ciaccio Hospital



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.